Gilead Sciences (GILD) Tops Q1 EPS by 31c
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $124.87 +0.90%
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.28 billion.
GUIDANCE:
Gilead Sciences sees Q2 2022 EPS of $6.20-$6.70, versus the consensus of $6.50. Gilead Sciences sees Q2 2022 revenue of $23.8-24.3 billion, versus the consensus of $24.48 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
